Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$160.79−0.31 (-0.19%)
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis Total R&D Pipeline Projects by Year
Novartis Total R&D Pipeline Projects: 99 in FY2025, down 2.0% from a year earlier.
Latest, FY2025
99
Period ended Dec 31, 2025
Change on a year earlier
-2.0%
101 in FY2024
History
3 years
Since FY2023
Sources
2
Documents cited below
Where the FY2025 figure comes from
“| Total projects in research and development | 99 | 101”
Source: Novartis Official IR / Sustainability Report — novartis-esg-data-summary-2025.pdf ↗
Reported in ESG Data Summary 2025 & Nonfinancial Report.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Total R&D Pipeline Projects | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 99 | -2.0% | Novartis Official IR / Sustainability Report — novartis-esg-data-summary-2025.pdf ↗ |
| FY2024 | Dec 31, 2024 | 101 | -7.3% | Novartis Official IR / Sustainability Report — novartis-esg-data-summary-2025.pdf ↗ |
| FY2023 | Dec 31, 2023 | 109 | – | Novartis Form 6-K (0001370368-24-000008) ↗ |
Breakdown
What makes up total R&D Pipeline Projects
Cite this data
StockData. (2026). Novartis Total R&D Pipeline Projects, annual FY2023–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/rd-pipeline-total-projects
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.